TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22932748

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21511226

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting Yukon Choice stent
Number of subjects: 240

Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting Taxus Liberté stent
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both stents
Number of subjects: 240
Study: 18305385

Group type: EXPERIMENTAL
Intervention: AN69ST membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FX100 membrane
Number of subjects: 10
Study: 16879326

Group type: EXPERIMENTAL
Intervention: 10 mg of melatonin and 50 mg of zinc acetate alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 10 mg of melatonin and 50 mg of zinc acetate in addition to metformin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 12884332

Group type: EXPERIMENTAL
Intervention: Fatty-meal MRC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no gallstones)
Number of subjects: 50
Study: 11117656

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d
Number of subjects: 4016

Group type: COMPARATOR
Intervention: TCAs
Number of subjects: 4016
Study: 8738538

Group type: EXPERIMENTAL
Intervention: Standard bicarbonate hemodialysis
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Continuous arteriovenous hemofiltration
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Daily recycled bicarbonate hemodialysis
Number of subjects: 141

Group type: COMPARATOR
Intervention: Group I vs Group II
Number of subjects: 141

Group type: COMPARATOR
Intervention: Within group comparison
Number of subjects: 141
Study: 1452502

Group type: EXPERIMENTAL
Intervention: Cefepime 1000 mg bd by constant infusion over 30 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6230176

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metaproterenol (1.3 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31766216

Group type: EXPERIMENTAL
Intervention: High dose (HD: 250 mg) of Amarasate®
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low dose (LD: 100 mg) of Amarasate®
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29197999

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 449
Study: 26810338

Group type: EXPERIMENTAL
Intervention: 41 mg enoxaparin subcutaneously plus 81 mg aspirin daily pre‐conception
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo pre‐conception
Number of subjects: 180
Study: 24196347

Group type: EXPERIMENTAL
Intervention: Cartilage resection method (CRM)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Suturing method (SM)
Number of subjects: 77
Study: 22064686

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention designed to produce and maintain weight loss
Number of subjects: 28735
Study: 20134098

Group type: EXPERIMENTAL
Intervention: Green tea catechins (high-dose group, 580 mg daily for 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Green tea catechins (medium-dose group, 80 mg daily for 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Green tea catechins (control group, 0 mg daily for 2 weeks)
Number of subjects: 30
Study: 18802804

Group type: EXPERIMENTAL
Intervention: Executive suppression task (random number generation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Articulatory suppression task
Number of subjects: 0
Study: 15843109

Group type: EXPERIMENTAL
Intervention: Relationship-based HIV/STI preventive intervention
Number of subjects: 388
Study: 12699026

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment with Contingency Management (CBT + CM)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Methadone Maintenance
Number of subjects: 108
Study: 10511320

Group type: EXPERIMENTAL
Intervention: Dietary calcium
Number of subjects: 0
Study: 7718263

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 84

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 84
Study: 1971445

Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) 200 mg BID
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Controlled Release (CR) 400 mg once daily
Number of subjects: 24
Study: 433821

Group type: EXPERIMENTAL
Intervention: Two whole fresh eggs daily for 3 months
Number of subjects: 116

Group type: COMPARATOR
Intervention: Elimination of eggs for 3 months
Number of subjects: 116
Study: 30717112

Group type: EXPERIMENTAL
Intervention: cyano‐B12 (2 × 0.76 µg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: cow milk (2 × 200 mL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: buffalo milk (2 × 200 mL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: combined B12 index (cB12)
Number of subjects: 67
Study: 28654131

Group type: EXPERIMENTAL
Intervention: Topical oxybutynin 10% gel
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo compound
Number of subjects: 61
Study: 26775474

Group type: EXPERIMENTAL
Intervention: Huikangling Tablet (HT), 0.4 g per tablet, 3 tablets each time, three times per day for 12 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (TSH suppression therapy only)
Number of subjects: 87
Study: 23602345

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1,200 mg
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 2,400 mg
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 3,600 mg
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study: 20862588

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 28
Study: 18455052

Group type: EXPERIMENTAL
Intervention: Letter explaining the importance of influenza vaccine for HCW
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Raffle ticket activated with influenza vaccine administration for a free Caribbean vacation for 2
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Both the educational letter and the raffle ticket
Number of subjects: 800

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 800
Study: 16821420

Group type: EXPERIMENTAL
Intervention: somatotropic therapy + coaxil (37.5 mg/day for 6 weeks; 25 mg/day for patients over 70 years)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: somatotropic therapy + coaxil
Number of subjects: 376

Group type: COMPARATOR
Intervention: somatotropic therapy alone (control group)
Number of subjects: 376
Study: 14571610

Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western medicine (ICWM)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (Western medicine)
Number of subjects: 49
Study: 10737842

Group type: EXPERIMENTAL
Intervention: Amoxicillin (50 mg/kg per day for 7 days)
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 1217
Study: 1578874

Group type: EXPERIMENTAL
Intervention: Hydroxypropylmethylcellulose (2%)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (1%)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Air
Number of subjects: 3
Study: 3905210

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg/day orally)
Number of subjects: 9
Study: 30696105

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) model
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model
Number of subjects: 288
Study: 29799982

Group type: EXPERIMENTAL
Intervention: Needle Aspiration (NA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Chest Drain (CD)
Number of subjects: 70
Study: 26576711

Group type: EXPERIMENTAL
Intervention: Goserelin every 3 months for 3 years and 4 cycles of docetaxel plus estramustine
Number of subjects: 413

Group type: COMPARATOR
Intervention: Goserelin alone
Number of subjects: 413
Study: 24534125

Group type: EXPERIMENTAL
Intervention: Automated Internet psycho-educational training program for depression
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Combination of automated Internet psycho-educational training program and Internet Support Group (ISG)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Internet Support Group (ISG)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control website
Number of subjects: 298
Study: 22534863

Group type: EXPERIMENTAL
Intervention: α-Galactosylceramide (α-GalCer)-pulsed antigen presenting cells (APCs)
Number of subjects: 4
Study: 20548043

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) plus standard medical care (SMC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard medical care (SMC) alone
Number of subjects: 66
Study: 18579812

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily
Number of subjects: 2531

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2531

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 2531
Study: 15961004

Group type: EXPERIMENTAL
Intervention: Levalbuterol (LEV) - <or=6 nebs LEV 1.25 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Racemic albuterol (RAC) combined with ipratropium bromide (IB) - <or=3 nebs RAC 5.0 mg + IB 0.25 mg followed as needed by <or=3 nebs RAC 5.0 mg
Number of subjects: 140
Study: 11972201

Group type: EXPERIMENTAL
Intervention: Helium insufflation (group 3, n = 43)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Helium + saline lavage (group 4, n = 40)
Number of subjects: 173

Group type: COMPARATOR
Intervention: CO2 insufflation (group 1, n = 47)
Number of subjects: 173

Group type: COMPARATOR
Intervention: CO2 + saline lavage (group 2, n = 43)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Saline peritoneal lavage (groups 2 and 4)
Number of subjects: 173
Study: 10433013

Group type: EXPERIMENTAL
Intervention: Anti-carbonic anhydrase II antibody testing in patients with PBC (n=40)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Anti-carbonic anhydrase II antibody testing in patients with AIC (n=23)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Anti-carbonic anhydrase II antibody testing in healthy subjects (n=24)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Anti-carbonic anhydrase II antibody testing in patients with autoimmune hepatitis (n=10)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Anti-carbonic anhydrase II antibody testing in patients with obstructive jaundice (n=10)
Number of subjects: 83
Study: 8754406

Group type: EXPERIMENTAL
Intervention: Nondialyzed (ND)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intermittent peritoneal dialysis (IPD)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 68
Study: 1387774

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg orally once daily for 3-5 consecutive days
Number of subjects: 31
Study: 6660847

Group type: EXPERIMENTAL
Intervention: Amoxicillin combined with clavulanic acid (ACA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 41
Study: 31711461

Group type: EXPERIMENTAL
Intervention: Factors associated with early termination of exclusive breastfeeding
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Having partners with formal education
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Receiving counseling on exclusive breastfeeding at antenatal check-up
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Giving birth in a health institution
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Initiating breastfeeding within the first hour
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Perceiving breast milk adequate for the first 6 months
Number of subjects: 484
Study: 29289538

Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acids (OM3-CA) 2 g daily
Number of subjects: 162

Group type: COMPARATOR
Intervention: Olive oil 2 g daily
Number of subjects: 162
Study: 27091416

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control (patient's choice with physician's advice of low-dose cytarabine or supportive care)
Number of subjects: 485
Study: 24957073

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no cetuximab)
Number of subjects: 69
Study: 22236405

Group type: EXPERIMENTAL
Intervention: Combination therapy with statins and fenofibric acid (FA)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Statins and fenofibric acid (FA)
Number of subjects: 1250
Study: 20351371

Group type: EXPERIMENTAL
Intervention: Deep needling
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Deep needling with bi-directional rotation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bi-directional needle rotation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Superficial needling
Number of subjects: 15
Study: 16707736

Group type: EXPERIMENTAL
Intervention: Phonological intervention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical exercise program
Number of subjects: 0
Study: 15718483

Group type: EXPERIMENTAL
Intervention: Active device (1-microm absolute ceramic filter and ultraviolet light); used for 6 months in cycle A and then switched to sham device for 6 months in cycle B.
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Sham device; used for 6 months in cycle A and then switched to active device for 6 months in cycle B.
Number of subjects: 1296
Study: 12001758

Group type: EXPERIMENTAL
Intervention: Radical Wertheim‐Meigs hysterectomy with ovarian preservation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (32 patients with stage IB carcinoma of the cervix without accompanying pregnancy)
Number of subjects: 18
Study: 10548322

Group type: EXPERIMENTAL
Intervention: High-fruit and -vegetable diet (9 daily servings)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 29
Study: 7788650

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 29
Study: 1922868

Group type: EXPERIMENTAL
Intervention: Thymostimulin
Number of subjects: 0
Study: 6753557

Group type: COMPARATOR
Intervention: Nifedipine (10 mg 3 times daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nifedipine (20 mg 3 times daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Verapamil (120 mg 3 times daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 56
Study: 30728074

Group type: EXPERIMENTAL
Intervention: High dose Shilajit (500 mg·d‐1)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Low dose Shilajit (250 mg·d‐1)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 28068560

Group type: EXPERIMENTAL
Intervention: Sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin 100 mg/day alone (ASA group)
Number of subjects: 40
Study: 26091087

Group type: EXPERIMENTAL
Intervention: telephone-delivered cognitive behavioural treatment (CBT) for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: waiting list control
Number of subjects: 80
Study: 24919799

Group type: EXPERIMENTAL
Intervention: Needling device treatment (3 treatments at 2-week intervals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 20
Study: 23390653

Group type: EXPERIMENTAL
Intervention: Original stimulating programs for correction of cognitive decline (computer programs, 20-30 minutes daily, 5 times a week for 14 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional methods of treatment
Number of subjects: 100
Study: 19751357

Group type: EXPERIMENTAL
Intervention: Inion GTR(TM) Biodegradable Membrane System
Number of subjects: 15

Group type: COMPARATOR
Intervention: Geistlich resorbable bilayer Bio‐Gide((R)) membrane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both membranes
Number of subjects: 15
Study: 17136555

Group type: EXPERIMENTAL
Intervention: Bipolar scissors
Number of subjects: 138

Group type: COMPARATOR
Intervention: Blunt dissection
Number of subjects: 138
Study: 15228194

Group type: EXPERIMENTAL
Intervention: Males and females within the same linguistic groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males of the two groups and females of the two groups
Number of subjects: 0
Study: 12205254

Group type: EXPERIMENTAL
Intervention: Sucrose (0.1 mL of 24%) administered orally up to 3 times, 2 minutes apart for every invasive procedure during a 7-day period
Number of subjects: 107

Group type: COMPARATOR
Intervention: Sterile water administered orally up to 3 times, 2 minutes apart for every invasive procedure during a 7-day period
Number of subjects: 107
Study: 10491709

Group type: EXPERIMENTAL
Intervention: Temporal vibrotactile display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatio-temporal vibrotactile display
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual‐Tactile (VT) conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual‐Alone (VA) conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tactile‐Alone (TA) conditions
Number of subjects: 0
Study: 7662240

Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine
Number of subjects: 54
Study: 2704600

Group type: EXPERIMENTAL
Intervention: B subunit
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 509959

Group type: EXPERIMENTAL
Intervention: One-contact-per-cycle schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-contact-per-cycle schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific symptom inquiry
Number of subjects: 0

Group type: COMPARATOR
Intervention: General inquiry
Number of subjects: 0
Study: 30909680

Group type: EXPERIMENTAL
Intervention: Thiocochlicoside (group A) along with paracetamol and lornoxicam I.V.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (group B) without thiocochlicoside, receiving paracetamol and lornoxicam I.V.
Number of subjects: 70
Study: 28216644

Group type: EXPERIMENTAL
Intervention: Antenatal lifestyle intervention
Number of subjects: 1555

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 1555
Study: 25837041

Group type: EXPERIMENTAL
Intervention: Endoscopic lung sealant (ELS) plus medical treatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 95
Study: 22417199

Group type: EXPERIMENTAL
Intervention: 3L‐1UB group (three‐set leg exercises and single‐set upper body exercises)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1L‐3UB group (single‐set leg exercises and three‐set upper body exercises)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3L‐1UB group
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1L‐3UB group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3L‐1UB group and 1L‐3UB group
Number of subjects: 21
Study: 22905666

Group type: EXPERIMENTAL
Intervention: Epidural tramadol (3 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Epidural lignocaine (4 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural tramadol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Epidural lignocaine
Number of subjects: 10
Study: 19623429

Group type: EXPERIMENTAL
Intervention: Side-opening cannula (SOC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Frontal-opening cannula (FOC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both SOC and FOC
Number of subjects: 31
Study: 17704869

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg PO, Metoclopramide 10 mg, Dexamethasone 4 mg, Ondansetron 4 mg IV
Number of subjects: 205
Study: 14980173

Group type: EXPERIMENTAL
Intervention: Drotrecogin alpha (activated)
Number of subjects: 0
Study: 11798012

Group type: EXPERIMENTAL
Intervention: Panax ginseng (PG) - 2 g/day dried root equivalent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eleutherococcus senticosus (ES) - 4 g/day dried root equivalent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9684719

Group type: EXPERIMENTAL
Intervention: Anterior approach for RF modification of AV node
Number of subjects: 33

Group type: COMPARATOR
Intervention: Posterior approach for RF modification of AV node
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Crossover to anterior approach
Number of subjects: 33

Group type: COMPARATOR
Intervention: Stepwise approach from posterior to anterior
Number of subjects: 33
Study: 7849498

Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms orally, 1 h prior to morphine)
Number of subjects: 15
Study: 3347080

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 ml of absolute alcohol per kg of body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Placebo (orange juice and vodka essence)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (orange juice)
Number of subjects: 30
Study: 31158914

Group type: EXPERIMENTAL
Intervention: Alliance Focused Training (AFT)
Number of subjects: 15
Study: 29557839

Group type: EXPERIMENTAL
Intervention: High-intensity functional anaerobic and progressive resistance training of the lower limbs (n = 8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Waitlist control group (n = 9)
Number of subjects: 17
Study: 28657451

Group type: EXPERIMENTAL
Intervention: Dedicated dietitians (DD)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Trained hospital dietitian (THD)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Existing practice (EP)
Number of subjects: 545